Incretins in Cardiometabolic Medicine: Leveraging GLP 1, GIP, and Glucagon Receptor Agonism for Cardiovascular Risk Reduction Targeting GLP 1, GIP & GCG in Obesity and Type 2 Diabetes Research Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP1, GIP, and Glucagon Agonists Khan 2026 Journal of Peptide Science Wiley Online Library Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit What is the pipeline for future medications for obesity? International Journal of Obesity Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link